These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Search MEDLINE/PubMed
Title: Itraconazole in the treatment of tinea corporis and tinea cruris: comparison of two treatment schedules. Author: Boonk W, de Geer D, de Kreek E, Remme J, van Huystee B. Journal: Mycoses; 1998 Dec; 41(11-12):509-14. PubMed ID: 9919895. Abstract: The efficacy and safety of two dos-ages of itraconazole in the treatment of tinea corporis or cruris were compared in a multicentre, randomized, double-blind, parallel-group trial. Fifty-four patients received itraconazole 100 mg daily for 2 weeks and 60 received itraconazole 200 mg daily for 1 week. After a 6-week follow-up period, mycological cure was achieved in 70% of patients in the 100 mg/2 weeks group and in 60% of those in the 200 mg/1 week group (not significantly equivalent); in the worst-case and intention-to-treat analyses, mycological cure rates (45-49%) were borderline equivalent at the end of follow-up. Clinical response was seen in 80% of evaluable patients in the 100 mg/2 weeks group and in 73% in the 200 mg/1 week group at the end of follow-up (borderline equivalent). Similar results were found in the intention-to-treat analysis. The tolerability ratings for the two regimens were significantly equivalent. Thirteen patients (24%) in the 100 mg/2 weeks group but only nine (15%) in the 200 mg/1 week group reported adverse events during treatment. Two patients in the 200 mg/1 week group stopped treatment because of adverse events. No clinically significant changes were seen in laboratory parameters in either treatment group. This trial showed that itraconazole 200 mg for 1 week is similarly effective, equally well tolerated and at least as safe as the established regimen of itraconazole 100 mg for 2 weeks in the treatment of tinea corporis or cruris.[Abstract] [Full Text] [Related] [New Search]